Clozapine treatment causes oxidation of proteins involved in energy metabolism in lymphoblastoid cells: A possible mechanism for antipsychotic- induced metabolic alterations

Journal of Psychiatric Practice

Volumn 16, Issue 5, 2010, Pages 325-333

  Baig, Muhammad R ^a   Navaira, Erica ^a   Escamilla, Michael A ^b   Raventos, Henriette ^c   Walss Bass, Consuelo ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSIDAD DE COSTA RICA   (Costa Rica)

Author keywords

antipsychotics; clozapine; glucose metabolism; oxidative stress; proteomics; reactive oxygen species

Indexed keywords

CLOZAPINE; COFILIN; CYSTEINE; CYTIDINE PHOSPHATE; ENOLASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR; PROTEIN; THIOL GROUP; TRIOSEPHOSPHATE ISOMERASE; URIDINE PHOSPHATE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROSPRAY; ELECTROSPRAY MASS SPECTROMETRY; ENERGY METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LYMPHOBLASTOID CELL; OXIDATIVE STRESS; PROTEIN METABOLISM; PROTEOMICS; SCHIZOPHRENIA; TWO DIMENSIONAL ELECTROPHORESIS;

ACTIN DEPOLYMERIZING FACTORS; ANTIPSYCHOTIC AGENTS; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FLUORESCEINS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; HUMANS; LYMPHOCYTES; NUCLEOSIDE-PHOSPHATE KINASE; OXIDATION-REDUCTION; PEPTIDE ELONGATION FACTORS; PHOSPHOPYRUVATE HYDRATASE; PROTEINS; PROTEOMICS; SCHIZOPHRENIA; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TRIOSE-PHOSPHATE ISOMERASE;

EID: 77957580499     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000388627.36781.6a     Document Type: Article

References (56)

1. Galili R, Mosberg, Gil-Ad I, et al. Haloperidol-induced neu-rotoxicity - possible implications for tardive dyskinesia. J Neural Transm 2000;107:479-90.
2. Miyamoto S, Duncan GE, Marx CE, et al. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005;10:79-104.
3. Ritchie CW, Chiu E, Harrigan S, et al. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsy-chotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psychiatry 2003;18:432-40.
4. Kopelowicz A, Zarate R, Tripodis K, et al. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry 2000;157: 987-93.
5. Keefe RS, Seidman LJ, Christensen BK, et al. Comparative effect of atypical and conventional antipsy-chotic drugs on neurocognition in first-episode psychosis: A randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004;161:985-95.
6. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998;155:914-20.
7. Kaneda Y, Kawamura I, Fujii A, et al. Impact of a switch from typical to atypical antipsychotic drugs on quality of life and gonadal hormones in male patients with schizophrenia. Neuro Endocrinol Lett 2004;25:135-40.
8. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsy-chotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003;160:1396-404.
9. Sanger TM, Lieberman JA, Tohen M, et al. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999;156:79-87.
10. Maudsley H. The pathology of mind, 3rd ed. New York: Appleton; 1880.
11. Jori A, Bianchetti A. Effect of chlorpromazine and of its metabolites on blood glucose and glucose tolerance. Int J Neuropharmacol 1966;5:435-40.
12. Korenyi C, Lowenstein B. Chlorpromazine induced diabetes. Dis Nerv Syst 1968;29:827-8.
13. Mennear JH, Miya TS. Chlorpromazine-induced glucose intolerance in the mouse. Proc Soc Exp Biol Med 1970;133: 770-3.
14. Cullen PD, Arney DC, Swartz HA. Chlorpromazine: Effect on food intake and glucose distribution in obese and nonobese mice. J Pharm Sci 1966;55:107-10.
15. Larsson S. The effect of chlorpromazine on the glucose metabolism in different parts of the goat brain. Acta Physiol Scand 1961;53:68-74.
16. Mraz M. The influence of chlorpromazine and pen-tamethonium on the carbohydrate metabolism and the resistance to trauma and to burn shock in rats. Arch Int Pharmacodyn Ther 1963;141:423-33.
17. Mueller PS, McDonald RK, Sribney M. Effect of chlorpro-mazine on rat fat metabolism. Proc Soc Exp Biol Med 1967;126:339-42.
18. Lehmann HE, Ban TA. The history of the psychopharma-cology of schizophrenia. Can J Psychiatry 1997;42:152-62.
19. Preskorn SH. Antipsychotic drug development in the prehuman-genome era: A full circle. J Psychiatr Pract 2001;7:209-13.
20. Haupt DW. Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol 2006;16(suppl 3):S149-55.
21. Newcomer JW. Second-generation (atypical) antipsy-chotics and metabolic effects: A comprehensive literature review. CNS Drugs 2005;19(suppl 1):1-93.
22. Rettenbacher MA. Disturbances of glucose and lipid metabolism during treatment with new generation antipsychotics. Curr Opin Psychiatry 2005;18:175-9.
23. Howes OD, Rifkin L. Diabetic keto-acidotic (DKA) coma following olanzapine initiation in a previously eugly-caemic woman and successful continued therapy with olanzapine. J Psychopharmacol 2004;18:435-7.
24. Sacher J, Mossaheb N, Spindelegger C, et al. Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology 2008;33: 1633-41.
25. Savoy YE, Ashton MA, Miller MW, et al. Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: Evidence for the involvement of sympathetic regulation. Schizophr Bull 2010;36:410-8.
26. Chintoh AF, Mann SW, Lam L, et al. Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J Clin Psychopharmacol 2008;28:494-9.
27. Houseknecht KL, Robertson AS, Zavadoski W, et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: Implications for adverse metabolic effects. Neuropsychopharmacology 2007;32:289-97.
28. Lemarie A, Huc L, Pazarentzos E, et al. Specific disintegration of complex II succinate: Ubiquinone oxidoreduc-tase links pH changes to oxidative stress for apoptosis induction. Cell Death Differ 2010 Aug 13 [Epub ahead of print].
29. Pamplona R, Portero-Otin M, Bellmun MJ, et al. Aging increases Nepsilon-(carboxymethyl)lysine and caloric restriction decreases Nepsilon-(carboxyethyl)lysine and Nepsilon-(malondialdehyde)lysine in rat heart mitochon-drial proteins. Free Radic Res 2002;36:47-54.
30. Ambrosio G, Zweier JL, Duilio C, et al. Evidence that mitochondrial respiration is a source of potentially toxic oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow. J Biol Chem 1993;268:18532-41.
31. Agostinho FR, Jornada LK, Schroder N, et al. Effects of chronic haloperidol and/or clozapine on oxidative stress parameters in rat brain. Neurochem Res 2007;32: 1343-50.
32. Polydoro M, Schroder N, Lima MN, et al. Haloperidol- and clozapine-induced oxidative stress in the rat brain. Pharmacol Biochem Behav 2004;78:751-6.
33. Reinke A, Martins MR, Lima MS, et al. Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosci Lett 2004;372:157-60.
34. Zhang XY, Tan YL, Cao LY, et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 2006;81:291-300.
35. Pillai A, Parikh V, Terry AV Jr, et al. Long-term antipsy-chotic treatments and crossover studies in rats: Differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2007;41:372-86.
36. Fehsel K, Loeffler S, Krieger K, et al. Clozapine induces oxidative stress and proapoptotic gene expression in neu-trophils of schizophrenic patients. J Clin Psychophar-macol 2005;25:419-26.
37. Kaneto H, Katakami N, Kawamori D, et al. Involvement of oxidative stress in the pathogenesis of diabetes. Antioxid Redox Signal 2007;9:355-66.
38. Befroy DE, Petersen KF, Dufour S, et al. Impaired mito-chondrial substrate oxidation in muscle of insulin-resistant offspring of type 2 diabetic patients. Diabetes 2007;56: 1376-81.
39. Zhang D, Liu ZX, Choi CS, et al. Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance. Proc Natl Acad Sci U S A 2007;104:17075-80.
40. Johannsen DL, Ravussin E. The role of mitochondria in health and disease. Curr Opin Pharmacol 2009;9:780-6.
41. Schrauwen P, Schrauwen-Hinderling V, Hoeks J, et al. Mitochondrial dysfunction and lipotoxicity. Biochim Biophys Acta 2010;1801:266-71.
42. Graham KA, Perkins DO, Edwards LJ, et al. Effect of olan-zapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005; 162:118-23.
43. Walss-Bass C, Weintraub ST, Hatch J, et al. Clozapine causes oxidation of proteins involved in energy metabolism: A possible mechanism for antipsychotic-induced metabolic alterations. Int J Neuropsychopharmacol 2008; 11:1097-104.
44. Walss-Bass C, Escamilla MA, Raventos H, et al. Evidence of genetic overlap of schizophrenia and bipolar disorder: Linkage disequilibrium analysis of chromosome 18 in the Costa Rican population. Am J Med Genet B Neuro-psychiatr Genet 2005;139B:54-60.
45. Baty JW, Hampton MB, Winterbourn CC. Detection of oxi-dant sensitive thiol proteins by fluorescence labeling and two-dimensional electrophoresis. Proteomics 2002;2: 1261-6.
46. Zhang Y, Padalecki SS, Chaudhuri AR, et al. Caspase-2 deficiency enhances aging-related traits in mice. Mech Ageing Dev 2007;128:213-21.
47. Martins-de-Souza D, Gattaz WF, Schmitt A, et al. Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry 2009;9:17.
48. Pretsch W. Triosephosphate isomerase activity-deficient mice show haemolytic anaemia in homozygous condition. Genet Res 2009;91:1-4.
49. Nakajima H, Amano W, Fujita A, et al. The active site cys-teine of the proapoptotic protein glyceraldehyde-3-phos-phate dehydrogenase is essential in oxidative stress-induced aggregation and cell death. J Biol Chem 2007;282:26562-74.
50. Chen Y, Deng Y, Zhang J, et al. GDI-1 preferably interacts with Rab10 in insulin-stimulated GLUT4 translocation. Biochem J 2009;422:229-35.
51. Klamt F, Zdanov S, Levine RL, et al. Oxidant-induced apoptosis is mediated by oxidation of the actin-regulatory protein cofilin. Nat Cell Biol 2009;11:1241-6.
52. Pasti C, Gallois-Montbrun S, Munier-Lehmann H, et al. Reaction of human UMP-CMP kinase with natural and analog substrates. Eur J Biochem 2003;270:1784-90.
53. Pearman AT, Castro-Faria-Neto HC, McIntyre TM, et al. Characterization of human UMP-CMP kinase enzymatic activity and 5' untranslated region. Life Sci 2001;69: 2361-70.
54. Anderson MA, Gusella JF. Use of cyclosporin A in establishing Epstein-Barr virus transformed human lym-phoblastoid cell lines. In Vitro 1984;20:856-8.
55. Pierce A, deWaal E, Van Remmen H, et al. A novel approach for screening the proteome for changes in protein conformation. Biochemistry 2006;45:3077-85.
56. Saurin AT, Neubert H, Brennan JP, et al. Widespread sulfenic acid formation in tissues in response to hydrogen peroxide. Proc Natl Acad Sci U S A 2004;101:17982-7.